IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gigliotti, F.
Right arrow Articles by Harmsen, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gigliotti, F.
Right arrow Articles by Harmsen, A. G.

 Previous Article  |  Next Article 

Infection and Immunity, March 2002, p. 1069-1074, Vol. 70, No. 3
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.3.1069-1074.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Passive Intranasal Monoclonal Antibody Prophylaxis against Murine Pneumocystis carinii Pneumonia

Francis Gigliotti,1,2* Constantine G. Haidaris,2 Terry W. Wright,1 and Allen G. Harmsen3

Department of Pediatrics,1 Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester,2 the Trudeau Institute, Saranac Lake, New York3

Received 17 July 2001/ Returned for modification 30 August 2001/ Accepted 8 November 2001

Passive antibody immunoprophylaxis is one method used to protect patients against infection if they are unable to mount an adequate active immune response. Topical application of antibody may be effective against infections at mucosal sites. Using a SCID mouse model of Pneumocystis carinii pneumonia, we were able to demonstrate protection against an airborne challenge with P. carinii by intranasal administration of antibody. Immunoglobulin M (IgM) monoclonal antibodies to an epitope shared by mouse and human P. carinii organisms reduced organism numbers by more than 99% under the conditions described. An IgG1 switch variant of one of the IgM monoclonal antibodies was also protective. These experiments provide a model for exploring the utility of this approach in protecting at-risk patients from infection with P. carinii.

* Corresponding author. Mailing address: Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642. Phone: (716) 275-5944. Fax: (716) 273-1104. E-mail: Francis_Gigliotti{at}urmc.rochester.edu.

Infection and Immunity, March 2002, p. 1069-1074, Vol. 70, No. 3
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.3.1069-1074.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2002 by the American Society for Microbiology. All rights reserved.